News related to Revlimid (Lenalidomide) and/or conditions it is approved for
REVLIMID (lenalidomide) approved by the European Commission for the treatment of relapsed/refractory patients with mantle cell lymphoma
Source: Cancer / Oncology News From Medical News Today [2016.07.18]
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation has announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult...
Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.06.07]
While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive...
Early Treatment of Smoldering Myeloma: Is It Time?
Source: Medscape Hematology-Oncology Headlines [2016.07.19]
The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice?
Medscape Medical News
Source: MedicineNet Amyloidosis Specialty [2016.04.01]
Title: Multiple Myeloma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/1/2016 12:00:00 AM
Empliciti Approved for Multiple Myeloma
Source: MedicineNet Multiple Myeloma Specialty [2015.12.01]
Title: Empliciti Approved for Multiple Myeloma
Category: Health News
Created: 11/30/2015 12:00:00 AM
Last Editorial Review: 12/1/2015 12:00:00 AM